This new agreement is in addition to the 300 million doses pledged to the EU through 2021 under the first supply agreement signed last year. The additional 200 million doses are expected to be delivered in 2021, with an estimated 75 million to be delivered in the second quarter.
The total number of doses to be delivered to EU member states by the end of 2021 is now at 500 million, with the potential to increase to 600 million based on the option provided in the new agreement.
“We recognize that more people need to be vaccinated as soon as possible to help fight this virus and control the global pandemic. We are working hard to support the rollout of vaccination campaigns in Europe and around the world by expanding manufacturing capacity, ”said Albert Bourla, chairman and chief executive, Pfizer. “With this new agreement with the European Commission, we now plan to deliver enough doses to vaccinate at least 250 million Europeans by the end of the year. “
“There is widespread access to well-tolerated and highly effective vaccines to stop the pandemic. We have taken further steps to expand our manufacturing capacity to two billion doses by 2021, ”said Ugur Sahin, MD, CEO and co-founder of BioNTech. “We will begin production at our Marburg facility this month and strengthen our manufacturing network with additional partners. We continue to evaluate, with governments, authorities and partners at all levels, how we might address an even higher supply requirement in the future for our vaccines. ”
COMIRNATY is manufactured at BioNTech and Pfizer manufacturing sites in Europe. COMIRNATY circulation by EU member states is carried out in accordance with the figures specified in EU and national guidelines. Globally, Pfizer and BioNTech aim to produce around two billion doses in total by the end of 2021, embracing ongoing process improvements, expansion at existing facilities, adding new suppliers and contract manufacturers and updated six-dose labels.
The vaccine, which is based on BioNTech ‘s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the custodian of Marketing Authorization in the EU, and the custodian of emergency use authority or similar in the United States, the United Kingdom, Canada and other countries before submitting a planned application for full marketing authority in the countries sin.